05.16.25 -- STREAM Edition: How Do Regulations Affect RNA Research?

Did you know the pharmaceutical industry's carbon footprint exceeds the automotive sector? Discover how drug companies and suppliers like Corning are forging a sustainable path forward.

Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases and oncology, how he reprioritized the company's development candidates and assimilated Sanofi's acquired T cell engager platform, and more.

QurAlis’ Kasper Roet describes the regulatory hurdles facing the RNA research space in the U.S. and why many companies are pursuing clinical work elsewhere.

Antibody-Drug Conjugates (ADCs) are a promising class of targeted cancer therapies. Learn about linker-payload design elements, conjugation and characterization of ADCs, and the different bioassays used to screen ADCs.

Explore how the various proprietary platforms and in-house expertise fit together to enable a range of comprehensive options that can be adapted to fit development strategies.

Watch to learn about a cost-effective platform for the production of antibodies. This flexible platform for single-use manufacturing maintains product quality comparable to current technologies.